Dr. Ghamande Discusses GOG/NRG 0265 Study in Cervical Cancer

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.

The phase II GOG/NRG-0265 study sought to identify pre-treatment baseline levels of serum proteins to establish overall survival benefit for patients with persistent or recurrent metastatic carcinoma of the cervix treated with axalimogene filolisbac.